AZ's Bydureon tops doc-payments list with $22B

When it comes to which brands spent the most on doctor payments, 2014 crowned a new king--and that's diabetes drug Bydureon. Maker AstraZeneca ($AZN) shelled out $22 million, helping the med eclipse Novo Nordisk's ($NVO) Victoza, one of last year's top spenders--and a head-to-head competitor. More from FiercePharmaMarketing

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.